Key points are not available for this paper at this time.
-mutated AML, CCR rates were higher with pevonedistat + azacitidine + venetoclax versus azacitidine + venetoclax. Safety was similar between treatment arms. Efficacy/safety with azacitidine + venetoclax was consistent with the phase 3 VIALE-A study. TRIAL REGISTRATION: NCT04266795.
Short et al. (Thu,) studied this question.